Leadership
Dr Bipin Patel - CEO
Dr Patel has 20+ years experience of pharmaceutical drug development and medtech commercialisation and is a serial entrepreneur. His areas of expertise include international business development, oncology drug discovery, and drug development. He has deep experience taking early scientific discoveries and realising their commercial potential. Dr. Patel has held executive leadership roles including Director, CEO, CCO, COO, SCO, BDO at early stage drug discovery and drug development companies, including established pharma & biotech players Merck, Pierre Fabre, GSK.
Dr Steven Powell - Chairman
After completing his Ph.D at the University of Aberdeen (UK), Steven began his career with Beecham. Pharmaceuticals (now GSK) and has subsequently held senior roles with both public and private companies in the UK, EU, USA and Canada. In the past 2 decades he has specialised in the translation of research into product development in both therapeutic and non-therapeutic fields. His clinical development experience includes oncology, neuroscience, infectious disease and urology. Steven’s most recent appointments include CEO of eTheRNA from 2018 to 2022, a mRNA company based in Belgium developing and manufacturing immunotherapeutics, and CEO of Ribonexus - a Paris based drug discovery company. He has been Chair of Cambridge Cognition plc, a UK publicly quoted digital neuroscience and biomarker business, since 2019.
Dr Alexander Scheer - R&D Drug Discovery
Dr Scheer holds a BSc in Natural Sciences and MSc in Chemistry, both from the University of Gottingen, and a PhD in Chemistry and Biochemistry from the German Cancer Research Center. He published more than 60 papers, book chapters or patents, and has more than 25 years of experience in R&D and the life science industry.
Professor Garth Cruickshank - Clinical Development Team
Prof. Cruickshank is a consultant neurologist at The University of Birmingham and Queen Elizabeth Hospitals, in the UK. He has served on editorial boards in the council of BNOG (Bristol Neuro-Oncology Group) and the NCRI (National Cancer Research Institute) Clinical Studies Group.
Dr Nikolai Nikolov - Clinical Development Team
Dr Nikolov holds a specialty in Anaesthesiology and Intensive Care and an EMBA degree. After several years of clinical practice, he joined the pharmaceutical industry. For more than 25 years he has held affiliate, regional and global positions of increasing responsibility. He has been involved in launching innovative products in rare diseases and specialty care.
Professor Jose Antonio Lozano - Clinical Development Team
Prof Jose Antonio Lozano has since 2005, led the Intelligent Systems Group (ISG), Computer Science School in San Sebastián, and, in 2018, he was appointed as Scientific Director at the Basque Center for Applied Mathematics in Bilbao. He has published four books, more than 100 scientific ISI journal articles, and about 150 contributions to national and international conferences.